<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03803631</url>
  </required_header>
  <id_info>
    <org_study_id>COCTAEyl</org_study_id>
    <nct_id>NCT03803631</nct_id>
  </id_info>
  <brief_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</brief_title>
  <acronym>COCTAEyl</acronym>
  <official_title>CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to analyze a new noninvasive imaging examination, OCT&#xD;
      angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet&#xD;
      AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Actual">January 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 13</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of collaterals on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of peripheral arcade on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arteriolization on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of vascular loops on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of dark halo on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of feeder vessel on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of flow void on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular area on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>baseline</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 1</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 2</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 3</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 4</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 5</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 6</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 7</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 8</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 9</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 10</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 11</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of neovascular density on OCTA</measure>
    <time_frame>at month 12</time_frame>
    <description>high flow on OCTA corresponding to the neovascular network with vascular remodeling over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraretinal and/or subretinal fluid in SD-OCT</measure>
    <time_frame>at month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at baseline</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 1</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 2</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 3</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 4</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 5</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 6</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 7</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 8</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 9</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 10</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 11</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 12</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity in logmar</measure>
    <time_frame>at month 13</time_frame>
    <description>Measure of best-corrected visual acuity (BCVA) measured on ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage, fibrosis and atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of hemorrhage on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of fibrosis on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence or abscence of atrophy on fundus color photography</measure>
    <time_frame>at 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)</measure>
    <time_frame>at month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>choroidal thickness on EDI-OCT</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of choroidal neovascularization on SD-OCT (type 1, type 2 or mixed lesions)</measure>
    <time_frame>monthly during 13 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>AMD</condition>
  <condition>Exudative Macular Degeneration</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with wet-AMD (NVC type 1 or 2) diagnosed maximum one week before inclusion and for&#xD;
        whom Aflibercept in intra-vitreal injection technic has been prescribed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Naïve patients&#xD;
&#xD;
          -  Type 1 or type 2 Choroidal NeoVascularization (CNV)&#xD;
&#xD;
          -  Age ≥ 55 years&#xD;
&#xD;
          -  Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD)&#xD;
&#xD;
          -  At the time of inclusion, multimodal imaging should reveal exudative features&#xD;
&#xD;
          -  Exudative AMD diagnosis established between 1 and 7 days before inclusion&#xD;
&#xD;
          -  Monitored monthly&#xD;
&#xD;
          -  Loading phase then bimonthly retreatment.&#xD;
&#xD;
          -  Signed Informed Consent.&#xD;
&#xD;
          -  Patient covered by the French Health Insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  Type 3 neovascularization&#xD;
&#xD;
          -  Choroidal neovascularization attributable to causes other than AMD&#xD;
&#xD;
          -  Macular hematoma&#xD;
&#xD;
          -  Pigment epithelial detachment higher than 150µm&#xD;
&#xD;
          -  Fibrosis &gt; 50% lesion on fundus color photography, fibroglial scar&#xD;
&#xD;
          -  Media opacity annoying acquisition&#xD;
&#xD;
          -  Retinal vascular occlusion&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies,&#xD;
&#xD;
          -  Refractive error &gt;-6D&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  Patient who does not meet the local indication criteria for Eylea® treatment.&#xD;
             Contraindications listed in the SmPCs must be taken into account&#xD;
&#xD;
          -  Patient taking part in an interventional study at the time of enrolment.&#xD;
&#xD;
          -  Any history of allergy to the antiseptic used during preparation of the eye for the&#xD;
             IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine).&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Stroke and/or myocardial infarction 3 months before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Pellegrin, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique d'Imagerie et de Laser,</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>June 6, 2023</last_update_submitted>
  <last_update_submitted_qc>June 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03803631
org study id: COCTAEyl
nct id: NCT03803631
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The main objective of this study is to analyze a new noninvasive imaging examination, OCT
      angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet
      AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.
observational model: Cohort
time perspective: Prospective
measure: presence of flow on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 13
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of collaterals on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of peripheral arcade on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of arteriolization on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of vascular loops on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of dark halo on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of feeder vessel on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: presence of flow void on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular area on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: baseline
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 1
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 2
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 3
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 4
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 5
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 6
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 7
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 8
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 9
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 10
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 11
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: measure of neovascular density on OCTA
time frame: at month 12
description: high flow on OCTA corresponding to the neovascular network with vascular remodeling over time
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 13
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at baseline
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 1
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 2
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 3
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 4
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 5
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 6
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 7
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 8
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 9
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 10
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 11
measure: Intraretinal and/or subretinal fluid in SD-OCT
time frame: at month 12
measure: visual acuity in logmar
time frame: at baseline
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 1
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 2
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 3
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 4
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 5
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 6
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 7
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 8
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 9
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 10
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 11
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 12
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: visual acuity in logmar
time frame: at month 13
description: Measure of best-corrected visual acuity (BCVA) measured on ETDRS
measure: presence or abscence of hemorrhage, fibrosis and atrophy on fundus color photography
time frame: at 1 months
measure: presence or abscence of hemorrhage on fundus color photography
time frame: at 1 months
measure: presence or abscence of fibrosis on fundus color photography
time frame: at 1 months
measure: presence or abscence of atrophy on fundus color photography
time frame: at 1 months
measure: presence or abscence of hemorrhage on fundus color photography
time frame: at 13 months
measure: presence or abscence of fibrosis on fundus color photography
time frame: at 13 months
measure: presence or abscence of atrophy on fundus color photography
time frame: at 13 months
measure: type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)
time frame: Baseline
measure: type of choroidal neovascularization on fluorescein angiography (type 1, type 2 or mixed lesions)
time frame: at month 13
measure: type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)
time frame: baseline
measure: type of choroidal neovascularization on indocyanine green angiography (type 1, type 2 or mixed lesions)
time frame: at month 13
measure: choroidal thickness on EDI-OCT
time frame: monthly during 13 months
measure: type of choroidal neovascularization on SD-OCT (type 1, type 2 or mixed lesions)
time frame: monthly during 13 months
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 55 Years
maximum age: N/A
healthy volunteers: No
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Macular Degeneration
mesh term: Wet Macular Degeneration
sharing ipd: Undecided